بدائل البحث:
aromatic decrease » dramatic decrease (توسيع البحث)
somatic decrease » dramatic decrease (توسيع البحث)
small decrease » small increased (توسيع البحث)
يعرض 521 - 540 نتائج من 2,241 نتيجة بحث عن '((aromatic decrease) OR (((somatic decrease) OR (small decrease))))', وقت الاستعلام: 0.39s تنقيح النتائج
  1. 521
  2. 522
  3. 523
  4. 524
  5. 525
  6. 526
  7. 527
  8. 528
  9. 529
  10. 530
  11. 531
  12. 532
  13. 533
  14. 534
  15. 535
  16. 536
  17. 537

    Table 3_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx حسب Joanna Palade (17712960)

    منشور في 2025
    "…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …"
  18. 538

    Table 7_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx حسب Joanna Palade (17712960)

    منشور في 2025
    "…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …"
  19. 539

    Image 1_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.jpg حسب Joanna Palade (17712960)

    منشور في 2025
    "…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …"
  20. 540

    Table 8_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx حسب Joanna Palade (17712960)

    منشور في 2025
    "…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …"